Brainsway Ltd Sponsored ADR Aktie News

Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings

Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression

BrainsWay Ltd. ( BWAY ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Carl Byrnes - Northland Capital Markets, Research Division Raghuram Selvaraju - H.C.

R evenue increase d 29% to $ 13.5 million in Q3 2025 as compared with Q 3 202 4

BURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tu...

R ecent agreements with two additional U.S. mental health providers bring total to four in 2025

This investment marks BrainsWay's entrance into the market for mental health therapies that can be administered outside of a clinic, including at home